RT Journal Article
T1 Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b
A1 Garcia-Garcia, Transito
A1 Fernandez-Rodriguez, Raul
A1 Redondo, Natalia
A1 de Lucas-Rius, Ana
A1 Zaldivar-Lopez, Sara
A1 Lopez-Ayllon, Blanca Dies
A1 Suarez-Cardenas, Jose M.
A1 Jimenez-Marin, Angeles
A1 Montoya, Maria
A1 Garrido, Juan J.
K1 Sars-cov
K1 Coronavirus
K1 Protein
K1 Cyclooxygenase-2
K1 Expression
K1 Adhesion
K1 Kegg
AB SARS-CoV-2, the causative agent of the present COVID-19 pandemic, possesses eleven accessory proteins encoded in its genome, and some have been implicated in facilitating infection and pathogenesis through their interaction with cellular components. Among these proteins, accessory protein ORF7a and ORF7b func-tions are poorly understood. In this study, A549 cells were transduced to express ORF7a and ORF7b, respectively, to explore more in depth the role of each acces-sory protein in the pathological manifestation leading to COVID-19. Bio-informatic analysis and integration of transcriptome results identified defined ca-nonical pathways and functional groupings revealing that after expression of ORF7a or ORF7b, the lung cells are potentially altered to create conditions more favorable for SARS-CoV-2, by inhibiting the IFN-I response, increasing proinflammatory cytokines release, and altering cell metabolic activity and adhe-sion. Based on these results, it is plausible to suggest that ORF7a or ORF7b could be used as biomarkers of progression in this pandemic.
PB Cell press
YR 2022
FD 2022-10-21
LK http://hdl.handle.net/10668/22279
UL http://hdl.handle.net/10668/22279
LA en
NO García-García T, Fernández-Rodríguez R, Redondo N, de Lucas-Rius A, Zaldívar-López S, López-Ayllón BD, et al. Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b. iScience. 2022 Nov 18;25(11):105444
NO The authors wish to acknowledge Bioinformatics & Biostatistics Service at CIB and Dr Aurora Go´ mez-Dura´ n. This research work was funded by: Junta de Andalucı´a project CV20-20089 (Call for Research Projects  on SARS-CoV-2 and COVID-19), the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) and the Spanish Ministry of Science project PID2021-123390B-I00
DS RISalud
RD Apr 7, 2025